esophageal cancer
Conditions
Interventions
Single arm group:re-irradiation combined with chemoimmunotherapy
Sponsors
Jiangsu Province Hospital, the first affiliated hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 80 years old; 2. The primary/primary focus was histologically diagnosed as esophageal squamous cell carcinoma; 3. Had previously received thoracic radiotherapy (>=50Gy), and imaging evaluation showed recurrence after radiotherapy; 4. The time interval between local recurrence and the end of the previous radiotherapy was more than 6 months; 5. The recurrent lesion was evaluated by thoracic surgery as an unresectable tumor, or the patient refused surgery, or the patient was evaluated to be unable to tolerate surgery for medical reasons; 6. KPS score is greater than or equal to 70, ECOG general status score is 0-1; 7. Adequate organ function and bone marrow function; 8. The location of the tumor should meet the requirements of the shooting field layout; Patients can lie on their back or stomach for more than 30 minutes in the position required for treatment.
Exclusion criteria
Exclusion criteria: 1. Complicated with other malignant tumors that have not been controlled; 2. The toxic side effects of the first radiotherapy have not recovered (including but not limited to: esophageal/tracheal fistula; radiation pneumonia; Class IV and above other toxic and side effects, etc.); 3. Previous radiotherapy of other organs in the chest; 4. Pacemakers or other metal implants that may be subject to high-energy radiation interference with normal function or that may affect the dose of the radiation target; 5. Accompanied by serious comorbidities that may affect radiotherapy; 6. Pregnant or lactating women; 7. Life expectancy is less than three months 8. The physician determines that further radiotherapy will not benefit the patient; 9. Inability to understand the purpose of treatment or unwillingness/inability to sign informed consent; 10. Other situations where participation in a clinical study is not considered appropriate by the physician.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Survival time after recurrence;Overall survival; | — |
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Duration of remission;(Disease control rate;Safety; | — |
Countries
China
Contacts
Public ContactXiaolin Ge
Jiangsu Province Hospital, the first affiliated hospital of Nanjing Medical University
Outcome results
None listed